Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $13,961.76 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 472 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $29.58, for a total transaction of $13,961.76. Following the completion of the sale, the insider now directly owns 17,331 shares in the company, valued at $512,650.98. This trade represents a 2.65 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Irene Becklund also recently made the following trade(s):

• On Monday, November 18th, Irene Becklund sold 472 shares of Hims & Hers Health stock. The shares were sold at an average price of $19.42, for a total transaction of $9,166.24.

Hims & Hers Health Trading Down 7.7 %

Shares of NYSE HIMS opened at $26.36 on Friday. The firm has a market capitalization of $5.76 billion, a PE ratio of 59.91 and a beta of 1.25. Hims & Hers Health, Inc. has a 12 month low of $8.09 and a 12 month high of $35.02. The firm has a fifty day simple moving average of $25.63 and a two-hundred day simple moving average of $21.23.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business’s revenue for the quarter was up 77.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.04) earnings per share. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Institutional Trading of Hims & Hers Health

A number of large investors have recently made changes to their positions in HIMS. Quest Partners LLC boosted its holdings in Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after buying an additional 807 shares in the last quarter. CWM LLC boosted its holdings in Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares during the period. Arizona State Retirement System lifted its position in shares of Hims & Hers Health by 3.0% during the 2nd quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock worth $815,000 after buying an additional 1,173 shares during the last quarter. Victory Capital Management Inc. boosted its stake in Hims & Hers Health by 6.6% during the 2nd quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock worth $393,000 after purchasing an additional 1,212 shares during the period. Finally, Nisa Investment Advisors LLC increased its stake in Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. TD Cowen reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. Morgan Stanley initiated coverage on Hims & Hers Health in a report on Tuesday. They set an “overweight” rating and a $42.00 price target on the stock. Piper Sandler reaffirmed a “neutral” rating and set a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Needham & Company LLC initiated coverage on Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Hims & Hers Health presently has an average rating of “Hold” and a consensus price target of $22.80.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.